We are live on ! Find out more
BMRN icon

BioMarin Pharmaceuticals
BMRN

341 hedge funds and large institutions have $13.4B invested in BioMarin Pharmaceuticals in 2014 Q4 according to their latest regulatory filings, with 58 funds opening new positions, 108 increasing their positions, 133 reducing their positions, and 27 closing their positions.

New
Increased
Maintained
Reduced
Closed

115% more first-time investments, than exits

New positions opened: 58 | Existing positions closed: 27

97% more call options, than puts

Call options by funds: $116M | Put options by funds: $59M

25% more capital invested

Capital invested by funds: $10.7B → $13.4B (+$2.68B)

22% more funds holding in top 10

Funds holding in top 10: 9 → 11 (+2)

8% more funds holding

Funds holding: 316 → 341 (+25)

19% less repeat investments, than reductions

Existing positions increased: 108 | Existing positions reduced: 133

Holders
341
Holders Change
+25
Holders Change %
+7.91%
% of All Funds
9.09%
Holding in Top 10
11
Holding in Top 10 Change
+2
Holding in Top 10 Change %
+22.22%
% of All Funds
0.29%
New
58
Increased
108
Reduced
133
Closed
27
Calls
$116M
Puts
$59M
Net Calls
+$57.3M
Net Calls Change
+$5.08M

Top Buyers

Rank Fund Capital Flow
1
Victory Capital Management
Victory Capital Management
Texas
+$120M
2
BBA
Baker Bros. Advisors
New York
+$112M
3
TCIM
TIAA CREF Investment Management
New York
+$104M
4
VAM
Visium Asset Management
New York
+$82.2M
5
Fidelity Investments
Fidelity Investments
Massachusetts
+$70.8M

Top Sellers

Rank Fund Capital Flow
1
State Street
State Street
Massachusetts
-$108M
2
Wells Fargo
Wells Fargo
California
-$86.5M
3
AGA
Altrinsic Global Advisors
Connecticut
-$77.4M
4
Alkeon Capital Management
Alkeon Capital Management
New York
-$54.6M
5
Point72 Asset Management
Point72 Asset Management
Connecticut
-$50M
Name Holding Trade Value Shares
Change 		Change in
Stake
SAM
26
Sectoral Asset Management
Quebec, Canada
$113M -$10.5M -125,757 -9%
BG
27
BlackRock Group
United Kingdom
$110M -$3.62M -43,489 -3%
First Trust Advisors
28
First Trust Advisors
Illinois
$106M +$1.76M +21,164 +2%
Deutsche Bank
29
Deutsche Bank
Germany
$104M -$16.3M -195,818 -15%
UBS AM
30
UBS AM
Illinois
$104M -$46K -553 -0%
GGHC
31
Gilder Gagnon Howe & Co
New York
$96.1M -$2.14M -25,748 -2%
BA
32
BlackRock Advisors
Delaware
$95.4M -$14.2M -171,041 -14%
Norges Bank
33
Norges Bank
Norway
$94.4M -$6.01M -72,230 -6%
VAM
34
Visium Asset Management
New York
$89.4M +$82.2M +988,391 New
Millennium Management
35
Millennium Management
New York
$82.8M +$19.1M +229,533 +33%
Invesco
36
Invesco
Georgia
$80.3M +$32.2M +387,805 +77%
Geode Capital Management
37
Geode Capital Management
Massachusetts
$70.6M +$2.05M +24,679 +3%
UIM
38
USS Investment Management
United Kingdom
$66.8M – – –
Ameriprise
39
Ameriprise
Minnesota
$65.8M +$32.6M +392,060 +117%
Alkeon Capital Management
40
Alkeon Capital Management
New York
$65.6M -$54.6M -656,600 -47%
Fidelity International
41
Fidelity International
Bermuda
$64.7M +$15.1M +180,982 +34%
AGA
42
Altrinsic Global Advisors
Connecticut
$64.5M -$77.4M -930,714 -57%
ClearBridge Investments
43
ClearBridge Investments
New York
$63.2M -$5.19M -62,435 -8%
Bank of New York Mellon
44
Bank of New York Mellon
New York
$54.3M +$381K +4,580 +0.8%
CS
45
Credit Suisse
Switzerland
$52.9M -$46.9M -563,800 -49%
Legal & General Group
46
Legal & General Group
United Kingdom
$51.7M -$2.39M -28,767 -5%
TCM
47
Tekla Capital Management
Massachusetts
$51.5M -$11.7M -140,500 -20%
Bank of America
48
Bank of America
North Carolina
$50.1M -$2.8M -33,676 -6%
JP Morgan Chase
49
JP Morgan Chase
New York
$50.1M +$5.18M +62,328 +13%
FCM
50
Frontier Capital Management
Massachusetts
$48.7M +$38M +457,271 +558%
1
2
3 4 5

BMRN Hedge Fund Activity: Q4 2014 in Review

341 of the 3,750 institutional investors tracked by Wall St. Rank reported a position in BioMarin Pharmaceuticals (BMRN) for Q4 2014, worth a combined $13.4B — up 25% from $10.7B a quarter earlier.

Buyers outnumbered sellers: 58 funds opened new BMRN positions and 27 closed out — a net gain of 31 holders — while 108 added to existing stakes and 133 trimmed.

The largest buyer was Victory Capital Management, opening a new position worth an estimated $120M. The largest seller was State Street, cutting an estimated $108M.

  • 341 institutional investors held BioMarin Pharmaceuticals (BMRN) as of Q4 2014, up from 316 in Q3 2014.
  • Funds reported $13.4B of BioMarin Pharmaceuticals stock for Q4 2014, up 25% quarter-over-quarter.
  • 58 funds opened new BioMarin Pharmaceuticals positions in Q4 2014 and 27 closed out, a net change of +31 holders.
  • The largest BioMarin Pharmaceuticals buyer in Q4 2014 was Victory Capital Management, an estimated $120M added.
  • The largest BioMarin Pharmaceuticals seller in Q4 2014 was State Street, an estimated $108M sold.

Based on aggregated 13F filings for Q4 2014.